Search
Levopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawnThis drug presented different dosages and it was administered as a capsule or suspension. … It was sold as an antitussive, but it was removed from the market in the 70s.[T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962.
Oxcarbazepine
go.drugbank.com/drugs/DB00776ApprovedInvestigational- a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine]. … [L8627,L8630,L8633] It is a structural derivative of [carbamazepine][A186101] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood
Products: OXCARBAZEPINA MYLAN GENERICSSofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalAs a prodrug nucleotide analog, Sofosbuvir is metabolized into its active form as the antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate (also known as GS-461203), which acts as a defective … Sofosbuvir is also available as a fixed dose combination product with [DB11613] as the commercially available product Epclusa.
Tridihexethyl
go.drugbank.com/drugs/DB00505ApprovedWithdrawnTridihexethyl is no longer available in the US market.
Tauroursodeoxycholic acid
go.drugbank.com/drugs/DB08834ApprovedInvestigationalWithdrawn[A249080] Tauroursodeoxycholic acid is currently used in Europe to treat and prevent gallstones as a bile acid derivative. … Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid [A249070] that is produced in humans at a low concentration.
Zotepine
go.drugbank.com/drugs/DB09225ApprovedWithdrawn[A31855] It has been used as an antipsychotic in Japan, India and some places in Europe like UK and Germany since 1980's.[A31857] Zotepine was never approved by the FDA. … In 1993, it was classified as inactive drug substance (Status I, Type II) and in 1995 the FDA studied the manufacturing procedures of Zotepine tablets in Germany, but the status remained inactive.
Medrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnMedrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. … It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.
Ansuvimab
go.drugbank.com/drugs/DB16385ApprovedInfection with pathogenic filoviruses, such as _Zaire ebolavirus_ (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as … However, to date, the most successful method appears to be the development of monoclonal antibodies (mAbs) against the GP<sub>1,2</sub> surface glycoprotein, as evidenced by the previously approved INMAZEB
Diatrizoate
go.drugbank.com/drugs/DB00271ApprovedVet approvedAs diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.
Cipaglucosidase alfa
go.drugbank.com/drugs/DB16708ApprovedInvestigationalCipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by a deficiency in GAA. Other types ...